share_log
Benzinga ·  Apr 29 16:22
Morphosys Group Ag Anticipates Close Of Proposed Acquisition By Novartis In H1 2024, Submit A New Drug Application For Pelabresib In Combination With Ruxolitinib In Myelofibrosis To FDA And Marketing Authorization Application To European Medicines Agency In H2 2024
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment